Advertisement

Topics

Novartis gains first-line approval for Zykadia in lung cancer

04:57 EDT 29 Jun 2017 | Pharmafile

The European Commission has followed the EMA’s CHMP positive opinion by approving Novartis’ Zykadia for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours are ALK-positive.

read more

Original Article: Novartis gains first-line approval for Zykadia in lung cancer

NEXT ARTICLE

More From BioPortfolio on "Novartis gains first-line approval for Zykadia in lung cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...